The role of fluorine in drug design and development is expanding rapidly as we learn more
about the unique properties associated with this unusual element and how to deploy it with …

Aggregation of amyloid-β (Aβ) into oligomers, fibrils, and plaques is central in the molecular
pathogenesis of Alzheimer's disease (AD), and is the main focus of AD drug development …

The accurate measurement of β-amyloid (Aβ) change using amyloid PET imaging is
important for Alzheimer disease research and clinical trials but poses several unique …

Amyloid imaging is a valuable tool for research and diagnosis in dementing disorders. As
positron emission tomography (PET) scanners have limited spatial resolution, measured …

One of the early pathological hallmarks of Alzheimer׳ s disease (AD) is the deposition of
amyloid-β (Aβ) plaques in the brain. There has been a tremendous interest in the …

Abstract 11 C-Pittsburgh compound B (PiB) is a positron emission tomography (PET) tracer
designed to bind to amyloid-β (Aβ) plaques, one of the hallmarks of Alzheimer's disease …

In vivo imaging of amyloid burden with positron emission tomography (PET) provides a
means for studying the pathophysiology of Alzheimer's and related diseases. Measurement …

Background Amyloid imaging using fluorine 18–labeled tracers florbetapir, florbetaben, and
flutemetamol has recently been reported in Alzheimer's disease (AD). Methods We …

PET amyloid imaging is increasingly used in research trials related to Alzheimer disease
and has potential as a quantitative biomarker. This study had 3 objectives: first, to describe a …

In evaluating disease changes, it is critical to have measurements that are sensitive, specific,
and reliable. Cognitive decline, particularly in the context of Alzheimer's disease, is an area …